Drugs Made In America Acquisition II (NASDAQ:DMII) Trading Up 0.1% – Should You Buy?

Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) shares traded up 0.1% during mid-day trading on Friday . The company traded as high as $9.98 and last traded at $9.97. 73,659 shares traded hands during trading, a decline of 41% from the average session volume of 123,897 shares. The stock had previously closed at $9.96.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings started coverage on shares of Drugs Made In America Acquisition II in a research report on Monday, March 2nd. They set a “sell (e)” rating on the stock. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Drugs Made In America Acquisition II Price Performance

Hedge Funds Weigh In On Drugs Made In America Acquisition II

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Sona Asset Management US LLC acquired a new stake in Drugs Made In America Acquisition II in the fourth quarter valued at approximately $2,970,000. Quarry LP purchased a new position in shares of Drugs Made In America Acquisition II in the fourth quarter valued at $990,000. PEAK6 LLC purchased a new position in shares of Drugs Made In America Acquisition II in the fourth quarter valued at $990,000. Royal Bank of Canada acquired a new stake in Drugs Made In America Acquisition II during the 4th quarter valued at $655,000. Finally, Virtu Financial LLC acquired a new stake in Drugs Made In America Acquisition II during the 4th quarter valued at $317,000.

Drugs Made In America Acquisition II Company Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.